基于生物信息学分析,识别与大动脉狭窄症中与免疫细胞相关的与氧化压力相关的基因
Shanghai Li1, Zhenjie Bai2, Jinhai Quan3
1Department of Cardiology, The First Clinical Medicine College of Jinan University, China. li.shanghai1981@163.com.
Cellular and molecular biology (Noisy-le-Grand, France)
|January 27, 2024
概括
这项研究揭示了氧化应激和免疫细胞透如何驱动大动脉狭窄症 (AS). 关键基因IGFBP2和SPHK1被确定为这种常见的膜心脏病的潜在治疗标.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 大动脉狭窄 (AS) 是最常见的膜心脏病,缺乏有效的药物治疗.
- 了解复杂的分子机制,包括氧化应激和免疫透,对于确定治疗点至关重要.
研究的目的:
- 用生物信息学研究大动脉狭窄症中氧化应激和免疫细胞透之间的相互作用.
- 确定AS治疗和早期检测的新型分子标.
主要方法:
- 使用GEO数据集 (GSE153555,GSE51472,GSE12644) 进行差异基因表达分析.
- 使用Cibersort进行免疫细胞透评估和WGCNA进行基因模块聚类.
- 交叉引用差异表达基因与来自GeneCards的氧化压力相关基因.
主要成果:
- 鉴定出1213个不同表达的基因,其中279个与氧化应激有关.
- 在AS中发现了天真B细胞和M1巨细胞的透增加.
- 突出显示IGFBP2和SPHK1在AS患者中显著上调,与特定的免疫细胞模块相关.
结论:
- IGFBP2和SPHK1与大动脉狭窄的病理生理学有关.
- 这些基因代表了早期检测的有希望的生物标志物和AS的潜在治疗点.
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


